CCSG - Administrative Supplement - ECIA

PROJECT SUMMARY Dr. Anand Patel is an academic hematologist/oncologist focused on developing clinical trials that investigate targeted therapies in acute leukemia and high-risk myeloid cancers. His goal is to initiate and lead both investigator-initiated clinical trials at his institution and multi-center NCI-sponsored cooperative group trials that help to identify effective novel therapies for high-risk blood cancers. Dr. Patel is an integral member of the University of Chicago Comprehensive Cancer Center (UCCCC); his roles include medical director of the inpatient leukemia service, member of the Protocol Review and Monitoring Committee (PRMC), and member of the Clinical and Experimental Therapeutics (CET) program. On a national level, Dr. Patel serves as the University of Chicago’s representative for the National Comprehensive Cancer Network’s panels for acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs). Furthermore, he is an active member of the Alliance for Clinical Trials in Oncology leukemia committee, the MyeloMATCH older adult AML working group, and the MyeloMATCH myelodysplastic syndrome (MDS) working group. Dr. Patel is an active clinical investigator; he has developed two investigator-initiated trials that are active to enrollment, serves as institutional principal investigator for 3 additional studies, and is the study chair for a protocol in development with the MyeloMATCH MDS working group and for a protocol being developed through the NCI’s Cancer Therapy Evaluation Program (CTEP). He also is an active co-investigator on several other protocols and contributes meaningfully to enrollment on these studies. The UCCCC fully supports Dr. Patel in his career development towards becoming a national leader in developing early-phase studies for acute leukemia and high-risk myeloid malignancies while also becoming an institutional leader within our cancer center. The ECIA award will serve to support the protected time necessary for Dr. Patel to complete his two investigator-initiated studies, develop national studies through MyeloMATCH and CTEP, and continue to gain experience with being an active member of our cancer center.